WO2022069579A3 - Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers - Google Patents

Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers Download PDF

Info

Publication number
WO2022069579A3
WO2022069579A3 PCT/EP2021/076848 EP2021076848W WO2022069579A3 WO 2022069579 A3 WO2022069579 A3 WO 2022069579A3 EP 2021076848 W EP2021076848 W EP 2021076848W WO 2022069579 A3 WO2022069579 A3 WO 2022069579A3
Authority
WO
WIPO (PCT)
Prior art keywords
hla
cancers
different types
against different
immunotherapy against
Prior art date
Application number
PCT/EP2021/076848
Other languages
French (fr)
Other versions
WO2022069579A2 (en
Inventor
Jens Hukelmann
Heiko Schuster
Lena Wullkopf
Christoph Schräder
Jens Fritsche
Daniel Kowalewski
Michael Römer
Oliver Schoor
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102020125465.2A external-priority patent/DE102020125465A1/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Priority to CA3193567A priority Critical patent/CA3193567A1/en
Priority to KR1020237013847A priority patent/KR20230079121A/en
Priority to CN202180080197.2A priority patent/CN116724048A/en
Priority to AU2021352111A priority patent/AU2021352111A1/en
Priority to EP21785884.4A priority patent/EP4221741A2/en
Priority to IL301444A priority patent/IL301444A/en
Priority to JP2023518954A priority patent/JP2023542998A/en
Publication of WO2022069579A2 publication Critical patent/WO2022069579A2/en
Publication of WO2022069579A3 publication Critical patent/WO2022069579A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/836—Intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]

Abstract

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
PCT/EP2021/076848 2020-09-29 2021-09-29 Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers WO2022069579A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA3193567A CA3193567A1 (en) 2020-09-29 2021-09-29 Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers
KR1020237013847A KR20230079121A (en) 2020-09-29 2021-09-29 Amidated peptides displayed by non-HLA-A*02 and their deamidated counterparts for use in immunotherapy for different types of cancer
CN202180080197.2A CN116724048A (en) 2020-09-29 2021-09-29 Amidated peptides displayed by non-HLA-A-02 for immunotherapy of different types of cancers and deamidated counterparts thereof
AU2021352111A AU2021352111A1 (en) 2020-09-29 2021-09-29 Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers
EP21785884.4A EP4221741A2 (en) 2020-09-29 2021-09-29 Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers
IL301444A IL301444A (en) 2020-09-29 2021-09-29 Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers
JP2023518954A JP2023542998A (en) 2020-09-29 2021-09-29 Amidated peptides presented by non-HLA-A*02 and their deamidated counterparts for use in immunotherapy against various types of cancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063084919P 2020-09-29 2020-09-29
US63/084,919 2020-09-29
DE102020125465.2 2020-09-29
DE102020125465.2A DE102020125465A1 (en) 2020-09-29 2020-09-29 Amidated peptides and their deamidated counterparts presented by non-HLA-A*02 molecules for use in immunotherapy against various types of cancer
US202163223291P 2021-07-19 2021-07-19
US63/223,291 2021-07-19

Publications (2)

Publication Number Publication Date
WO2022069579A2 WO2022069579A2 (en) 2022-04-07
WO2022069579A3 true WO2022069579A3 (en) 2022-07-07

Family

ID=78049255

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/076848 WO2022069579A2 (en) 2020-09-29 2021-09-29 Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers

Country Status (8)

Country Link
EP (1) EP4221741A2 (en)
JP (1) JP2023542998A (en)
KR (1) KR20230079121A (en)
AU (1) AU2021352111A1 (en)
CA (1) CA3193567A1 (en)
IL (1) IL301444A (en)
TW (1) TW202229312A (en)
WO (1) WO2022069579A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020327A1 (en) * 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DD147855A5 (en) 1978-12-22 1981-04-22 Biogen Nv METHOD OF GENERATING AT LEAST ONE HBV ANTIGEN IMPACT POLYPEPTIDE
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
ES2138662T3 (en) 1993-06-03 2000-01-16 Therapeutic Antibodies Inc PRODUCTION OF ANTIBODY FRAGMENTS.
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
AU4289496A (en) 1994-12-02 1996-06-19 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
ATE244300T1 (en) 1996-01-17 2003-07-15 Imp College Innovations Ltd IMMUNOTHERAPY USING CYTOTOXIC T LYMPHOCYTES (CTL)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE472601T1 (en) 2000-03-27 2010-07-15 Technion Res And Dev Of Founda CLASS I SINGLE-CHAIN MAIN HISTOCOMPATIBILITY COMPLEXES (MHC-I), CODING CONSTRUCTS AND METHODS OF THEIR GENERATION
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
ES2649037T3 (en) 2000-12-12 2018-01-09 Medimmune, Llc Molecules with prolonged half-lives, compositions and uses thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20030223994A1 (en) 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
JP4436319B2 (en) 2002-10-09 2010-03-24 メディジーン リミテッド Single-chain recombinant T cell receptor
NZ539226A (en) 2002-11-09 2008-09-26 Medigene Ltd T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
KR20070039911A (en) 2004-06-01 2007-04-13 도만티스 리미티드 Bispecific fusion antibodies with enhanced serum half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
BR112013010213A2 (en) 2010-10-26 2019-09-24 Technion Research & Development Foundation Ltd antibodies that bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
ES2603589T3 (en) 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Nucleic acids encoding chimeric polypeptides for systematic library identification
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020327A1 (en) * 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALTRICH-VANLITH MICHELLE L. ET AL: "Processing of a Class I-Restricted Epitope from Tyrosinase Requires Peptide N -Glycanase and the Cooperative Action of Endoplasmic Reticulum Aminopeptidase 1 and Cytosolic Proteases", THE JOURNAL OF IMMUNOLOGY, vol. 177, no. 8, 15 October 2006 (2006-10-15), US, pages 5440 - 5450, XP055884236, ISSN: 0022-1767, Retrieved from the Internet <URL:https://www.jimmunol.org/content/jimmunol/177/8/5440.full.pdf> DOI: 10.4049/jimmunol.177.8.5440 *
MEI SHUTAO ET AL: "Immunopeptidomic Analysis Reveals That Deamidated HLA-bound Peptides Arise Predominantly from Deglycosylated Precursors", MOLECULAR & CELLULAR PROTEOMICS, vol. 19, no. 7, 1 May 2020 (2020-05-01), US, pages 1236 - 1247, XP055883978, ISSN: 1535-9476, DOI: 10.1074/mcp.RA119.001846 *

Also Published As

Publication number Publication date
IL301444A (en) 2023-05-01
TW202229312A (en) 2022-08-01
KR20230079121A (en) 2023-06-05
JP2023542998A (en) 2023-10-12
EP4221741A2 (en) 2023-08-09
WO2022069579A2 (en) 2022-04-07
AU2021352111A1 (en) 2023-05-04
CA3193567A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
EP2573109A3 (en) Peptide vaccines comprising Seq Id 101, 80 or 100 for cancers expressing tumor-associated antigens
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
MX2009004147A (en) Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides.
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
RU2015103816A (en) CELLING PEPTIDES IN THE CELL, THE TARGET OF WHICH IS THE eIF4E
MX2022005922A (en) Prame tcr receptors and uses thereof.
JP2019527066A5 (en)
CA2581110A1 (en) Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions
MX2009007261A (en) Foxp3 peptide vaccine.
WO2008113970A3 (en) Peptides
RU2012136464A (en) MELK MODIFIED PEPTIDES AND THEIR VACCINES CONTAINING THEM
NZ603611A (en) Insulin-like growth factor 1 receptor binding peptides
WO2011135222A3 (en) Use of peptides as transporters intended for the internalization of molecules of interest into target cells
EP1842911A4 (en) Hla-binding peptides, dna fragments encoding the same and recombinant vectors
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
WO2022069579A3 (en) Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers
MX2010005816A (en) Stat3 epitope peptides.
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
MX2023003367A (en) Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancers.
JP2012527867A5 (en)
RU2011140168A (en) VANGL1 PEPTIDES AND THEIR VACCINES CONTAINING THEM
RU2011130796A (en) C1ORF59 PEPTIDES AND THEIR VACCINES CONTAINING THEM
NZ603379A (en) Ect2 peptides and vaccines including the same
JP2019038772A5 (en)
WO2020150313A1 (en) Amphipathic alpha-helical antimicrobial peptides treat infections by gram-negative pathogens

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: AU2021352111

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 3193567

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2023518954

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20237013847

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021352111

Country of ref document: AU

Date of ref document: 20210929

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021785884

Country of ref document: EP

Effective date: 20230502

WWE Wipo information: entry into national phase

Ref document number: 202180080197.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21785884

Country of ref document: EP

Kind code of ref document: A2